UPDATE: TALAPRO-2 Links Circulating Tumor DNA and Cancer Cell Clearance to Longer Progression-Free Survival
A new exploratory analysis of the Phase 3 TALAPRO-2 trial, published in The Lancet Oncology, has identified important relationships between circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that blood-based biomarkers could provide valuable information about prognosis and treatment response beyond conventional PSA measurements.
TALAPRO-2 enrolled 805 patients who received either talazoparib plus enzalutamide or enzalutamide with placebo. The new analysis focused on the ability of liquid biopsies to identify DNA repair alterations and monitor changes in circulating tumor material during treatment.
One important result was the 84% agreement between tumor tissue and ctDNA testing for homologous recombination repair (HRR) gene alterations among 501 evaluable patients. Agreement increased to 89% when the tumor DNA fraction in blood was at least 1%, supporting the potential of liquid biopsies as a complementary tool for molecular profiling.
Baseline ctDNA detectability was strongly associated with progression-free survival. In patients receiving talazoparib plus enzalutamide, median radiographic progression-free survival was 21.0 months when ctDNA was detectable, compared with a median not yet reached when it was undetectable. In the enzalutamide-only group, the corresponding figures were 11.0 and 33.2 months.
Changes during treatment were equally informative. Among patients initially positive for ctDNA, those who became ctDNA-negative by week 9 experienced longer median radiographic progression-free survival than those who remained positive: 25.9 versus 10.8 months with talazoparib plus enzalutamide, and 16.5 versus 5.5 months with enzalutamide alone.
Circulating tumor cell reductions also showed a strong association with outcomes. In the talazoparib group, patients whose CTC counts declined from at least five to four or fewer cells per 7.5 mL of blood by week 9 achieved a median radiographic progression-free survival of 22.1 months, compared with 5.5 months in patients without this conversion. In the control group, the corresponding figures were 16.6 versus 3.6 months.
These findings strengthen the case for using liquid biopsies not only to identify actionable mutations but also to monitor how metastatic prostate cancer responds to treatment. Early reductions in circulating tumor DNA and cancer cells could help researchers identify patients experiencing deeper and more durable disease control.

Leave a Reply
Want to join the discussion?Feel free to contribute!